Skip to content
OpenCapital
Get started

Syndax Pharmaceuticals SNDX Increase (Decrease) in Accounts Receivable

Increase (Decrease) in Accounts Receivable at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$6.5M+110%
Gilead Sciences logo
Gilead SciencesGILD
——

Other financials

Income statement

See full
Revenue$64.9M+224%
Operating income-$34.2M+59.2%
Net income-$42.7M+49.7%
EPS (diluted)-$0.48+51.0%

Balance sheet

See full
Cash & equivalents$130.9M-15.0%
Total debt$350.5M+4.2%
Total equity$41.6M-80.6%
Total assets$472.7M-26.2%

Cash flow

See full
Operating cash flow-$50.3M+47.1%
CapEx$46.8K—
Free cash flow-$80.8M-17.6%

Valuation

See full
Market cap$1.77B+95.0%
Enterprise value$1.99B+84.0%
P/S8.1×-12.6×

Profitability

See full
Operating margin-102.8%-47.8pp
Net margin-111.9%-51.5pp
FCF margin-187.2%-85.4pp

Returns & leverage

See full
Return on equity-189.5%-8,509pp
Debt / equity8.4×+6.9×
Current ratio5.5×-0.3×

Where this comes from

Reported directly by Syndax Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.

The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Syndax Pharmaceuticals's increase (decrease) in accounts receivable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Syndax Pharmaceuticals's increase (decrease) in accounts receivable?
Syndax Pharmaceuticals (SNDX) reported increase (decrease) in accounts receivable of -$120K in Q1 2026.
How has Syndax Pharmaceuticals's increase (decrease) in accounts receivable changed year-over-year?
Syndax Pharmaceuticals's increase (decrease) in accounts receivable decreased by 101.5% year-over-year, from $8.12M to -$120K.